About abvc biopharma - ABVC
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.
ABVC At a Glance
ABVC BioPharma, Inc.
44370 Old Warm Springs Boulevard
Fremont, California 94538
| Phone | 1-510-668-0881 | Revenue | 509.59K | |
| Industry | Pharmaceuticals: Major | Net Income | -4,902,878.00 | |
| Sector | Health Technology | 2024 Sales Growth | 234.31% | |
| Fiscal Year-end | 12 / 2025 | Employees | 19 | |
| View SEC Filings |
ABVC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 13.516 |
| Price to Book Ratio | 6.673 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.923 |
| Enterprise Value to Sales | 16.995 |
| Total Debt to Enterprise Value | 0.37 |
ABVC Efficiency
| Revenue/Employee | 26,820.474 |
| Income Per Employee | -258,046.211 |
| Receivables Turnover | 0.441 |
| Total Asset Turnover | 0.045 |
ABVC Liquidity
| Current Ratio | 0.332 |
| Quick Ratio | 0.332 |
| Cash Ratio | 0.142 |
ABVC Profitability
| Gross Margin | 60.422 |
| Operating Margin | -923.34 |
| Pretax Margin | -1,053.707 |
| Net Margin | -962.124 |
| Return on Assets | -43.612 |
| Return on Equity | -97.418 |
| Return on Total Capital | -110.678 |
| Return on Invested Capital | -91.558 |
ABVC Capital Structure
| Total Debt to Total Equity | 261.286 |
| Total Debt to Total Capital | 72.321 |
| Total Debt to Total Assets | 42.49 |
| Long-Term Debt to Equity | 19.313 |
| Long-Term Debt to Total Capital | 5.346 |